Sigyn Therapeutics appoints Annette Marleau, Ph.D. as Chief Scientific Officer

Sigyn Therapeutics, Inc.

Appointed Annette Marleau, Ph.D. as Chief Scientific Officer, effective immediately.
Previously CTO at Immunicom and Director of Research at Aethlon Medical, advancing blood purification for cancer.
Awarded over $6 million in NIH grants; co-authored two FDA-cleared IDEs and a Breakthrough Device submission.
Inventor on patents for blood purification therapies targeting cancer, inflammatory disorders, and infectious diseases.
Her expertise supports Sigyn's pipeline including Sigyn Therapy, ChemoPrep, and ChemoPure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.